Clinical Trial Update: Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a completed Phase 1/2 trial evaluating the safety, tolerability and maximum tolerated dose of SPINALON in adults with chronic spinal cord…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• SPINALON

Snippet

Sponsor: Nordic Life Science Pipeline Inc. | Conditions: Spinal Cord Injury | Phase 1, Phase 2 | Status: COMPLETED